Compounds, chelates and their applications in magnetic resonance imaging
By developing chelates formed by bicyclic polyazacea macrocyclic carboxylic acid ligand compounds and metal ions, the shortcomings of existing gadolinium bicyclic polyazacea macrocyclic carboxylic acid chelates in terms of stability and relaxation rate are solved. , achieving high relaxation and good pharmacokinetic characteristics, reducing the risk of free Gd3+ release, and providing a better magnetic resonance imaging contrast agent.
Patent Information
- Application Number
- CN202411290102.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-09-14
AI Technical Summary
The existing gadolinium bicyclic polyaza macrocyclic carboxylic acid chelates have room for improvement in chelation stability, water solubility and relaxation, and gadolinium magnetic resonance imaging contrast agents may lead to adverse reactions in clinical applications. Such as deposition and allergic reactions of free Gd3+.
Develop a chelate formed by bicyclic polyazacea macrocyclic carboxylic acid ligand compounds with metal ions (such as Gd3+), which has high relaxation and good pharmacokinetic characteristics, through optimized structural design and synthesis methods, Improve chelation stability and solubility and reduce the release of free Gd3+.
It achieves high relaxation and good pharmacokinetic characteristics, overcomes the problem of free Gd3+ release of gadolinium-based contrast agents after intravenous injection, reduces the risk of adverse reactions, and provides better options for magnetic resonance imaging contrast agents.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_27
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical imaging, and in particular relates to a compound, a metal chelate of the compound, and application of the compound in a magnetic resonance imaging contrast agent. Background Art
[0002] Magnetic resonance imaging (MRI) is based on the energy transition of atomic nuclei with magnetic moments under the action of a magnetic field, and uses the magnetic resonance principle to image the difference in hydrogen nucleus density between different tissues of the human body. Due to the low sensitivity of MRI, contrast agents are needed to improve the imaging contrast between the lesion site and healthy tissue. Among them, MRI contrast agents containing paramagnetic and superparamagnetic metals are currently the most commonly used MRI contrast agents because they can obtain stronger signals and higher spatial resolution due to changes in proton relaxation time and increased relaxation rate.
[0003] The first paramagnetic MRI contrast agent put into clinical use in 1983 was a chelate of diethylenetriaminepentaacetic acid (DTPA) and Gd (III) (Gd-DTPA) developed by Schering Company of Germany. It can effectively shorten the spin-lattice relaxation time (T1) of tissues and is currently the most widely used MRI positive contrast agent. However, in actual applications, it was found that because Gd-DTPA is a small molecule ionic contrast agent with a high osmotic pressure in the body, it quickly enters the intercellular space after entering the blood, is easily metabolized by the kidneys and quickly excreted, has a short retention time in the body, has poor tissue or organ selectivity, and is expensive. In view of this, it is necessary to develop a MRI contrast agent with better performance, such as high relaxation rate, good solubility, and high stability, to improve the efficiency of diagnostic imaging.
[0004] In the currently known patent literature, patent document EP 438206 discloses a bicyclopolyazamacrocyclocarboxylic acid chelate as shown in the following formula:
[0005]
[0006] Wherein, X represents a carboxylate / salt or phosphate / salt group, R0 represents an alkyl group or a phenyl group, or R0 is a group that forms a bond with a biological molecule, wherein PCTA is a bicyclic polyazamacrocyclic carboxylic acid chelate well known to those skilled in the art, and the relaxation rate of PCTA is about 4-6mM -1 ∙S -1 ∙Gd -1 .
[0007] Furthermore, patent document WO93 / 11800 discloses that the R0 group in the above formula is selected from H, OH or C1-C3 alkyl. Patent document US5403572 discloses that the R0 group can be an alcohol compound, and the synthesis method of the compound includes first synthesizing the alcohol chain, and then coupling the chain with the macrocyclic nitrogen atom through an alkylation reaction. Patent document US6450956 discloses that the R0 group is -CH2-CH2-CO-NY-Y, wherein Y is a heavy amino alcohol chain, such as the molecular weight of the amino alcohol chain is 500-1500. Although the design makes the compound have a higher relaxation rate, it also brings the problems of expensive synthesis and excessive viscosity of the compound.
[0008] On this basis, patent document CN 103224495A discloses a bicyclic polyazamacrocyclic carboxylic acid chelate as shown in the following formula:
[0009]
[0010] Wherein, X represents C1-C3 alkyl, Y represents -CONH2, -CO-NR7R8 or -NR7-CO-R8, and R7 and R8 are independently selected from H, C1-C6 alkyl, C1-C6 hydroxyalkyl. The relaxation rate of the chelate at 0.5T in water disclosed in the patent document is 9-15mM∙S -1 ∙Gd -1 .
[0011] With the development of magnetic resonance imaging technology, the use of gadolinium-based magnetic resonance imaging contrast agents has increased year by year. Although it is generally believed that gadolinium contrast agents are safe, some patients still experience adverse reactions, such as headache, nausea, taste changes or urticaria. A very small number of patients may develop anaphylactic shock or nephrogenic systemic fibrosis in the long term. Some preclinical studies have shown that intravenous injection of gadolinium-based contrast agents can release free Gd 3+ , free Gd 3+ It can be rapidly distributed to the bones and liver, with a small amount of deposition. Therefore, the chelation stability of gadolinium contrast agents is a key factor to be considered during drug development.
[0012] The present invention technicians have found in long-term research that the existing gadolinium bicyclic polyazamacrocyclic carboxylic acid chelates have room for further improvement in terms of chelation stability, water solubility and relaxivity. Based on this, the present invention has developed a ligand compound and a chelate formed by the ligand compound and metal ions, and the chelate has the advantages of high relaxivity and high stability, and has potential clinical application prospects as a magnetic resonance imaging contrast agent. Summary of the invention
[0013] The object of the present invention is to provide a bicyclic polyazamacrocyclic carboxylic acid ligand compound, wherein the ligand compound chelates with metal ions to form a chelate, and the chelate has good stability and high relaxivity, and has the potential to be developed as a magnetic resonance imaging contrast agent for clinical application. Another object of the present invention is to provide a preparation method of the chelate and a pharmaceutical composition containing the chelate.
[0014] The purpose of the present invention is achieved through the following technical solutions:
[0015] In the first aspect of the present invention, the present invention provides a ligand compound as shown in formula I, or an enantiomer thereof, or a diastereomer thereof, or a pharmaceutically acceptable salt thereof:
[0016] ;
[0017] Among them, G is selected from OR a NR b R c , SR d , where R a , R b , R c , R d are independently selected from hydrogen, deuterium, hydroxyalkyl, mercaptoalkyl, alkoxyalkyl, thioetheralkyl, aminoalkyl, substituted aminoalkyl, carboxylalkyl, esteralkyl, amidealkyl, phenyl, phenylalkyl, aromatic heterocyclic group, aromatic heterocyclic group alkyl, heterocyclic group, heterocyclic group alkyl or a group selected from the following:
[0018] C1-C6 alkyl, C3-C6 cycloalkyl,
[0019] wherein the C1-C6 alkyl is optionally substituted identically or differently by a phenyl substituent, and the phenyl substituent is optionally substituted identically or differently 1, 2 or 3 times by a halogen atom or a group selected from the following:
[0020] Hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy.
[0021] Preferably, G is -OH or -OCH3.
[0022] R1, R2, R3 are independently selected from -COOH, carboxylate / salt, -P(O)(OH)2, R e -P(O)(OH)2, phosphate ester / salt, R e Selected from H or C1-C3 alkylene.
[0023] X is selected from C1-C6 alkyl.
[0024] Y stands for -CO-NR f R g or -NRf -CO-R g , where R f , R g Each independently represents H or C1-C6 alkyl or C l -C6 hydroxyalkyl, and R f or R g At least one representative C l -C6 hydroxyalkyl.
[0025] Preferably, Y is -AB-R4, wherein A is selected from -CO-; B is selected from -N(R5)-, R5 is selected from H, C1-C3 alkyl, C1-C3 hydroxyalkyl; and R4 is selected from C1-C6 hydroxyalkyl.
[0026] K1-K8 are each independently selected from H, -(CH2) j -CH3 or (CH2) i -OH, wherein j is 0-8 and i is 1-8.
[0027] Preferably, K1-K8 are each independently selected from -H, C1-C6 alkyl, C1-C6 hydroxyalkyl.
[0028] The C1-C6 alkyl group described in the present invention is selected from any C1, C2, C3, C4, C5, C6 straight-chain or branched alkyl group known to those skilled in the art.
[0029] Preferably, the C1-C6 alkyl group includes but is not limited to -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-CH2-.
[0030] The C1-C6 hydroxyalkyl group of the present invention is selected from a C1, C2, C3, C4, C5, C6 straight or branched alkyl group containing one or more hydroxyl groups. l -C6 hydroxyalkyl groups include but are not limited to -CH2-CH2OH, -CHOH-CH2OH, -CH-(CH2OH)2, -(CH2) p -(CHOH) q -CH2OH, wherein p=1-3, q=1-4, and p+q=2-5, or -C-(CH2OH)3.
[0031] The C1-C3 alkyl or C1-C3 hydroxyalkyl described in the present invention is as defined above and will not be repeated here.
[0032] Furthermore, the present invention provides ligand compounds as shown in Formula II-1 and Formula II-2:
[0033] ;
[0034] In the above formula, n is selected from an integer between 1 and 6, specifically 1, 2, 3, 4, 5, and 6.
[0035] R5 is selected from H, C1-C2 alkyl, C1-C2 hydroxyalkyl;
[0036] Specifically, the C1-C2 alkyl group is selected from -CH3 and -CH2-CH3; the C1-C2 hydroxyalkyl group is selected from -CH2OH and -CH2-CH2OH.
[0037] R4 is , wherein R6 and R7 are selected from H or -CH2OH, and m is selected from an integer between 0 and 4, specifically 0, 1, 2, 3, 4. When m is 0, it means that the -CHOH- group does not exist.
[0038] In one embodiment of the present invention, the ligand compound is as shown in Formula III-1a or Formula III-1b:
[0039] ;
[0040] In the above formula, n is selected from 1, 2 or 3; m is selected from 0, 1, 2, 3 or 4. When m is 0, it means that the -CHOH- group does not exist.
[0041] R5 is selected from H, -CH3 or -CH2-CH2OH.
[0042] R8, R9, R 10 are each independently selected from H or -CH2OH, and R8, R9, R 10 At least one of them is -CH2OH; preferably, R8, R9, R 10 Two of them are -CH2OH; more preferably, R8, R9, R 10 All are -CH2OH.
[0043] In another embodiment of the present invention, the ligand compound is as shown in Formula III-2a or Formula III-2b:
[0044] (III-2a), (III-2b);
[0045] In the above formula, n is selected from 1, 2 or 3; m is selected from 0, 1, 2, 3 or 4. When m is 0, it means that the -CHOH- group does not exist.
[0046] R5 is selected from H, -CH3 or -CH2-CH2OH.
[0047] R8, R9, R 10 are each independently selected from H or -CH2OH, and R8, R9, R 10 At least one of them is -CH2OH; preferably, R8, R9, R 10 More preferably, R8, R9, R 10 All are -CH2OH.
[0048] In the most preferred embodiment of the present invention, the ligand compound is selected from the following structures:
[0049] , ,
[0050] , ,
[0051] , ,
[0052] , , , , , , , , , , , .
[0053] The ligand compound of the present invention also includes its stereoisomers, tautomers, N-oxides, hydrates, solvates or mixtures thereof.
[0054] The ligand compound of the present invention also includes a multimer formed by the above ligand compound, and the multimer is preferably a dimer, trimer or tetramer.
[0055] The ligand compound of the present invention also includes a conjugate obtained by coupling the above ligand compound with any peptide, protein or monoclonal antibody via a bonding group.
[0056] The bonding groups include amino, hydroxyl, carboxyl, carbonyl, thiol, thioether and the like.
[0057] Common peptides in the art that can be coupled with the ligand compound include, but are not limited to, ingr polypeptide, NGR polypeptide, Pasireotide, Triptorelin polypeptide, and Octreotide.
[0058] In the second aspect of the present invention, the present invention provides a chelate, which is a chelate of the ligand compound described in the first aspect of the present invention and a metal ion, wherein the metal ion is selected from paramagnetic metal ions or radioactive nuclide ions.
[0059] The paramagnetic metal ion is selected from Gd 3+ , Mn 2+ , Yb 3+ or Fe 3+ .
[0060] The radionuclide ions are selected from 99 Tc, 117 Sn, 111 In, 97 Such as 67 Ga, 89 Zr, 177 Lu, 47 Sc, 105 Rh, 188 Re, 60 Cu, 62 Cu, 64 Cu, 67 Cu, 90 Y. 159 Gd, 149 Pr or 166 Ho.
[0061] Preferably, the chelate is a ligand compound described in the first aspect of the present invention and Gd 3+ of chelates.
[0062] Specifically, the chelate has a structure shown in Formula AO-Ⅰ:
[0063]
[0064] (AO-Ⅰ)
[0065] In the formula, G, X, Y, K1-K8, R1, R2 and R3 are as described in the first aspect of the present invention.
[0066] Furthermore, the chelate has the structure shown in Formula AO-II-1 and Formula AO-II-2:
[0067]
[0068] In the formula, n, R4 and R5 are as described in the first aspect of the present invention.
[0069] Furthermore, the chelate has the structure shown in Formula AO-III-1a, Formula AO-III-1b, Formula AO-III-2a, Formula AO-III-2b:
[0070]
[0071] In the formula, n, m, R5, R8, R9, R 10 As described in the first aspect of the present invention.
[0072] In a preferred embodiment of the present invention, the chelate has the following structural formula:
[0073] , ,
[0074] , ,
[0075] , ,
[0076] , , , , , , , , , , , .
[0077] In the third aspect of the present invention, the present invention provides a method for preparing a chelate, comprising the following steps:
[0078]
[0079] In the formula, G, n, R4 and R5 are as described in the first aspect of the present invention.
[0080] As shown in the above formula, compound M2 is dissolved in water, the pH is adjusted to 6, compound M1 and dioxane are added, HOBT and EDCI are added under stirring, the pH of the reaction solution is adjusted to 6, the reaction is carried out for 24 hours, and the solution is concentrated under reduced pressure. An equal volume of ethanol and ether are added to disperse the solid, and the solution is filtered and separated by reverse phase preparative chromatography to obtain chelate M.
[0081] In the fourth aspect of the present invention, the present invention provides a pharmaceutical composition, which comprises the ligand compound described in the first aspect of the present invention or the chelate described in the second aspect of the present invention, and a pharmaceutically acceptable excipient or adjuvant.
[0082] The use of the pharmaceutically acceptable adjuvant or auxiliary agent depends on the specific composition and the specific mode of administration. The pharmaceutical composition of the present invention has various suitable formulations, including but not limited to lipid nanoparticles prepared by the ligand compound or chelate.
[0083] In the fifth aspect of the present invention, the present invention provides a use of the ligand compound described in the first aspect of the present invention, the chelate described in the second aspect of the present invention or the pharmaceutical composition described in the fourth aspect of the present invention in the preparation of a contrast agent for magnetic resonance imaging.
[0084] The ligand compound provided by the present invention and Gd 3+ The chelate formed by chelation exhibits high relaxivity and good pharmacokinetic characteristics. The technicians of the present invention unexpectedly found that the chelate prepared by the present invention has higher chelation stability and solubility, especially in plasma, and also exhibits excellent chelation stability, overcoming the problem that conventional gadolinium contrast agents release free Gd after intravenous injection. 3+ to prevent patients from suffering from free Gd 3+ Adverse reactions. 3+ Chelates have potential clinical application prospects as magnetic resonance imaging contrast agents. DETAILED DESCRIPTION
[0085] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0086] Explanation of terms
[0087] The term "C1-C6 alkyl" refers to any straight chain or branched chain group of C1, C2, C3, C4, C5, C6 well known to those skilled in the art.
[0088] The term "C1-C6 hydroxyalkyl" refers to a C1, C2, C3, C4, C5, C6 straight or branched chain group containing one or more hydroxyl groups.
[0089] The term "pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal to be treated therewith.
[0090] The term "pharmaceutically acceptable excipients or adjuvants" may include any solvents, solid excipients, diluents or other liquid excipients, etc., suitable for a particular target dosage form.
[0091] The following is further described by specific examples. It should be understood that these examples are only used for more detailed description and should not be understood as limiting the present disclosure in any form.
[0092] The compound names corresponding to the English abbreviations described in the present invention are as follows:
[0093] HCl: hydrochloric acid
[0094] EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
[0095] HOBT: 1-Hydroxybenzotriazole
[0096] Gd2O3: Gadolinium oxide
[0097] The structures of the compounds in the embodiments of the present invention were determined by nuclear magnetic resonance ( 1 H-NMR) or liquid chromatography-mass spectrometry (LC-MS) for characterization. The "room temperature" in the present invention refers to 10-25°C.
[0098] G 3+ Preparation of chelates
[0099] Example 1 Synthesis of Chelate 1
[0100]
[0101] 0.88 g (9.7 mmol, 3.6 eq) of 3-amino-1,2-propanediol was dissolved in 50 ml of water, and the pH of the reaction solution was adjusted to 6 with 2N HCl. 2.11 g (2.7 mmol, 1 eq) of compound X and 40 ml of dioxane were added to the reaction solution. 1.57 g of HOBT (11.6 mmol, 4.3 eq) and 2.22 g of EDCI (11.6 mmol, 4.3 eq) were added under stirring, and the pH of the reaction solution was adjusted to 6. After reacting for 24 hours, the reaction solution was concentrated under reduced pressure to about 20 ml. 100 ml of ethanol and 100 ml of ether were added to the reaction bottle to disperse the solid, and the solid was filtered and separated by reverse phase preparative chromatography to obtain 0.86 g (32%, 0.86 mmol) of chelate 1 of Example 1 with a purity of 97.8%.
[0102] LC-MS(ESI+): m / z=1001.2(M+H) + .
[0103] Example 2 Synthesis of Chelate 2
[0104]
[0105] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-aminoethanol to obtain the chelate 2 of Example 2 with a purity of 98.2%.
[0106] LC-MS(ESI+): m / z=911.1(M+H) + .
[0107] Example 3 Synthesis of Chelate 3
[0108]
[0109] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-amino-1,3-propanediol to obtain chelate 3 of Example 3 with a purity of 97.3%.
[0110] LC-MS(ESI+): m / z=1001.3(M+H) + .
[0111] Example 4 Synthesis of Chelate 4
[0112]
[0113] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 3-(methylamino)-1,2-propanediol to obtain chelate 4 of Example 4 with a purity of 97.2%.
[0114] LC-MS(ESI+): m / z=1043.3(M+H) + .
[0115] Example 5 Synthesis of Chelate 5
[0116]
[0117] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-amino-2-hydroxymethyl-1,3-propanediol to obtain chelate 5 of Example 5 with a purity of 98.4%.
[0118] LC-MS(ESI+): m / z=1091.3(M+H) + .
[0119] Example 6 Synthesis of Chelate 8
[0120]
[0121] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with glucosamine to obtain the chelate 8 of Example 6 with a purity of 97.4%.
[0122] LC-MS(ESI+): m / z=1271.5(M+H) + .
[0123] Example 7 Synthesis of Chelate X
[0124]
[0125] Synthesis of compound Int.3:
[0126] 4.73g (20.0 mmol, 1eq) of Int.1 (see J. Am. Chem. Soc. 2018, 140, 11, 3916–3928 for synthesis), 17.10g (64.0 mmol, 3.2eq) of diethyl 2-bromoglutarate and 11.06g (80.0mmol, 4eq) of anhydrous K2CO3 were added to 500ml of acetonitrile and heated under reflux and stirred overnight. After the reaction was completed, the reaction solution was filtered while hot, the solid was washed with acetonitrile and the filtrate was concentrated. The concentrate was chromatographed on a silica gel column to obtain 11.61g (73%, 14.6mmol) of the target compound Int.3 with a purity of 95.2%.
[0127] LC-MS(ESI+): m / z=795.8(M+H) + .
[0128] 1 H NMR (400 MHz, CDCl3) δ 6.72 (s, 2H), 4.18 – 4.12 (m, 12H), 3.88 – 3.62 (m, 10H), 2.89 – 2.81 (m, 2H), 2.80 – 2.72 (m, 2H), 2.65 – 2.55 (m, 4H), 2.51 – 2.32 (m, 6H), 2.08 – 1.81 (m, 6H), 1.26 – 1.23 (m, 18H).
[0129] Synthesis of compound Int 4:
[0130] 10.00 g (12.6 mmol) of Int.3 was dissolved in a mixed solution of 60 ml of 5N sodium hydroxide and 60 ml of methanol. The reaction solution was heated under reflux and stirred for 5-8 hours. After the reaction was completed, the reaction solution was concentrated, dissolved in water, and the aqueous solution was ion exchanged through Amberlite IRC50 resin. The obtained solution was concentrated and solidified and crystallized with ethanol to obtain 6.77 g (86%, 10.8 mmol) of the target compound Int.4 with a purity of 95.8%.
[0131] LC-MS(ESI+): m / z=627.7(M+H) + , LC-MS(ESI-): m / z=625.4(MH) + .
[0132] 1 H NMR (400 MHz, CD3OD) δ 6.70 (s, 2H), 3.84 – 3.76 (m, 5H), 3.70 – 3.60 (m, 5H), 2.86 – 2.73 (m, 4H), 2.62 – 2.54 (m, 4H), 2.48 – 2.29 (m, 6H),2.06 – 1.73 (m, 6H).
[0133] Synthesis of Chelate X:
[0134] 6.27 g (10.0 mmol) of Int.4 was dissolved in 150 ml of water, the pH was adjusted to 6, 1.99 g (5.5 mmol) of Gd2O3 was added to the solution, and the reaction solution was heated to 60°C for 8 hours. The reaction solution was concentrated and solidified and crystallized with ethanol to obtain 6.09 g (78%, 7.8 mmol) of the target chelate X with a purity of 96.7%.
[0135] LC-MS(ESI+): m / z=782.3(M+H) + .
[0136] Example 8 Synthesis of Chelate 10
[0137]
[0138] The preparation method is the same as that of Example 1, except that the chelate X in Example 1 is replaced by the chelate Y, so that the chelate 10 of Example 8 can be prepared with a purity of 96.8%.
[0139] LC-MS(ESI+): m / z=987.4(M+H) + .
[0140] Example 9 Synthesis of Chelate 11
[0141]
[0142] The preparation method is the same as that of Example 2, except that the chelate X in Example 2 is replaced by the chelate Y, so that the chelate 11 of Example 9 can be prepared with a purity of 96.2%.
[0143] LC-MS(ESI+): m / z=897.3(M+H) + .
[0144] Example 10 Synthesis of Chelate 12
[0145]
[0146] The preparation method is the same as that of Example 3, except that the chelate X in Example 3 is replaced by the chelate Y, so that the chelate 12 of Example 9 can be obtained with a purity of 98.3%.
[0147] LC-MS(ESI+): m / z=987.2(M+H) + .
[0148] Example 11 Synthesis of Chelate 13
[0149]
[0150] The preparation method is the same as that of Example 4, except that the chelate X in Example 4 is replaced by the chelate Y, so that the chelate 13 of Example 11 can be prepared with a purity of 98.4%.
[0151] LC-MS(ESI+): m / z=1029.3(M+H) + .
[0152] Example 12 Synthesis of Chelate 14
[0153]
[0154] The preparation method is the same as that of Example 5, except that the chelate X in Example 5 is replaced by the chelate Y, so that the chelate 14 of Example 12 can be prepared with a purity of 97.7%.
[0155] LC-MS(ESI+): m / z=1077.5(M+H) + .
[0156] Example 13 Synthesis of Chelate 17
[0157]
[0158] The preparation method is the same as that of Example 6, except that the chelate X in Example 6 is replaced by the chelate Y, so that the chelate 17 of Example 13 can be prepared with a purity of 97.4%.
[0159] LC-MS(ESI+): m / z=1257.4(M+H) + .
[0160] Example 14 Synthesis of Chelate Y
[0161]
[0162] Synthesis of compound Int.6:
[0163] The preparation method is the same as the preparation method of Int.3 in Example 7, except that Int.1 in the preparation method is replaced by Int.5 (refer to Chem. Commun., 2013, 49, 2712-2714 for synthesis), to obtain compound Int.6 with a purity of 96.1%.
[0164] LC-MS(ESI+): m / z=871.6(M+H) + .
[0165] 1 H NMR (400 MHz, CDCl3) δ 7.46 – 7.41 (m, 2H), 7.37 – 7.33 (m, 2H), 7.32 – 7.25 (m, 1H), 6.70 (s, 2H), 4.99 (s, 2H), 4.18 – 4.09 (m, 12H), 3.87 –3.61 (m, 7H), 2.88 – 2.80 (m, 2H), 2.78 – 2.70 (m, 2H), 2.63 – 2.52 (m, 4H), 2.51 – 2.32 (m, 6H), 2.08 – 1.81 (m, 6H), 1.26 – 1.23 (m, 18H).
[0166] Synthesis of compound Int 7:
[0167] 8.70 g (10.0 mmol) of Int.7 was added to 100 ml of methanol solution, and 1.22 g (10.0 mmol, 1 eq) of palladium oxide was added to the reaction system to catalyze the hydrogenation reaction to remove the benzyl group. After the reaction, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The concentrate was chromatographed on a silica gel column to obtain 5.08 g (65%, 6.5 mmol) of the target compound Int.7 with a purity of 97.3%.
[0168] LC-MS(ESI+): m / z=781.7(M+H) + .
[0169] 1 H NMR (400 MHz, CDCl3) δ 6.56 (s, 2H), 4.15– 4.11 (m, 12H), 3.86 – 3.70 (m, 5H), 3.61 – 3.58 (m, 2H), 2.90 – 2.81 (m, 2H), 2.80 – 2.71 (m, 2H), 2.63 – 2.53 (m, 4H), 2.52 – 2.31 (m, 6H), 2.07 – 1.81 (m, 6H), 1.26 – 1.23 (m, 18H).
[0170] Synthesis of compound Int 8:
[0171] The preparation method is the same as the preparation method of Int.4 in Example 7, except that Int.3 in the preparation method is replaced by Int.7, to obtain compound Int.8 with a purity of 95.2%.
[0172] LC-MS(ESI+): m / z=613.4(M+H) + ;
[0173] 1 H NMR (400 MHz, CD3OD) δ 6.60 (s, 2H), 3.82 – 3.80 (m, 2H), 3.68 – 3.64 (m, 5H), 2.85 – 2.74 (m, 4H), 2.62 – 2.54 (m, 4H), 2.48 – 2.29 (m, 6H),2.05 – 1.81 (m, 6H).
[0174] Synthesis of Chelate Y:
[0175] The preparation method is the same as the preparation method of chelate X in Example 7, except that Int.4 in the preparation method is replaced by Int.8 to obtain chelate Y with a purity of 95.6%.
[0176] LC-MS(ESI+): m / z=768.2(M+H) + .
[0177] Comparative Example 1 Synthesis of Chelate 1-Gadopiclenol
[0178]
[0179] The chelate 1-Gadopiclenol was prepared according to the preparation method of Example 2 in patent CN101305006A as comparative example 1 of the present invention, and purified by reverse phase preparative chromatography and dried to obtain the target comparative example 1 compound with a purity of 97.5%. The structural identification was consistent, and the LC-MS (ESI+) of the main product was: m / z=971.1 (M+H) + , that is, the molecular weight of the main product is 970.1. The chemical structure of the product is the same as that shown in Comparative Example 1 above.
[0180] Effect Test Example 1 Relaxivity Measurement at 3.0 T
[0181] Relaxivity measurements at 3.0 T were performed by a whole-body 3.0 T MRI scanner using a knee coil. The sample tubes were placed in tubes 4 and 5 of 3 columns in a plastic holder in a box filled with water, and the temperature was adjusted to 37°C.
[0182] For the MRI sequence, the shortest possible echo time (TE) of 7.46 milliseconds was used. The inversion times were selected to optimize the sequence to measure T1 values corresponding to the estimated T1 range of all relaxation times of the contrast-containing solution. The following inversion times (TI) were used: 50, 100, 150, 200, 300, 500, 700, 1000, 1400, 2100, 3200 and 4500 milliseconds. After registration of the last echo, the sequence was run at a constant relaxation delay of 3.4 seconds (the range of variable TR was 3450-7900 milliseconds).
[0183] Relaxivity was assessed using three different concentrations of each compound (3 concentrations ranging from 0.05 to 2 mM).
[0184] The T1 relaxation times of the example compounds were measured in water and human plasma. Human plasma preparation: For each experiment, fresh blood was taken from volunteers using a 10 mL citrate tube. The 10 mL citrate tube was carefully inverted ten times to mix the blood and anticoagulant and centrifuged at room temperature for 15 minutes.
[0185] The relaxivity r1 was calculated based on the relaxation time T1 measured in water and plasma:
[0186]
[0187] Wherein “T1 intrinsic” is the relaxation time corresponding to the blank solvent, and “[contrast agent]” represents the concentration of the compound standardized to gadolinium. The results are shown in Table 1.
[0188] Table 1 Relaxivities in water and human plasma at 3.0T, 37°C (normalized to Gd) [L / mmol / s]
[0189]
[0190] From the results in the above table, it can be seen that the relaxivities of the chelates 1-5, 8, 10-14 and 17 prepared by the present invention are significantly stronger than 1-Gadopiclenol, which proves that the chelates 1-5, 8, 10-14 and 17 of the present invention have better contrast effects; in particular, the relaxivities of the chelates 5, 8, 14 and 17 are more prominent, and the contrast effects are more advantageous.
[0191] Effect Test Example 2 Chelation Stability Measurement in Tris-HCl Buffer
[0192] The chelate prepared in the present example and the chelate of comparative example 1 were dissolved in 10 mM Tris-HCl buffer (pH 7.4) to a final concentration of 5 mmol Gd / L. An aliquot was removed and the rest of the clear and colorless solution was autoclaved at 121°C for 20 min; after autoclaving, the solution was still clear and colorless. The Gd released from the chelate before and after autoclaving was determined by HPLC-ICP-MS. 3+ The amount of Gd before and after autoclaving was monitored by ICP-MS. 3+ The results are shown in the following table:
[0193] Table 2 Gd in solution 3+ The release amount
[0194]
[0195] Note: The limit of quantification is 0.1% of the total amount of gadolinium.
[0196] From the results in the above table, it can be seen that the stability of the chelates 1, 5, 8, 14, and 17 prepared by the present invention in Tris-HCl buffer is better than that of 1-Gadopiclenol. In the detection system of the chelates 1, 5, 8, 14, and 17, no chromatographic changes before and after high-pressure sterilization were detected, indicating that the chelates prepared by the present invention are stable during the high-pressure sterilization operation. 3+ The release amounts were all less than 0.1%, which was below the limit of quantification, and the stability was better than that of 1-Gadopiclenol.
[0197] Effect Test Example 3 Measurement of Chelation Stability in Plasma
[0198] The chelate prepared in the present embodiment and the chelate prepared in comparative example 1 were dissolved in human plasma at 1 mmol Gd / L. 0.1 mmol / L gadolinium chloride (GdCl3) was dissolved in human plasma as the released Gd 3+The plasma samples were incubated at 37°C in a 5% CO2 atmosphere for 15 days, maintaining the pH at 7.4. Aliquots were taken at the beginning and end of the incubation, and the Gd released from the chelate was determined by HPLC-ICP-MS. 3+ The amount of Gd was specifically monitored by ICP-MS, and the chromatogram changes of the intensity of the monitored Gd were evaluated by peak area analysis. The results are shown in the following table:
[0199] Table 3 Gd in plasma 3+ The release amount
[0200]
[0201] Note: The limit of quantification is 0.1% of the total amount of gadolinium
[0202] From the results in the above table, it can be seen that no chromatographic changes before and after the measurement were detected in the detection system of chelates 1, 5, 8, 14, and 17 prepared by the present invention, indicating that there is no free Gd in the system. 3+ ions, indicating that chelates 1, 5, 8, 14, and 17 are stable in plasma. 3+ The release amount is less than 0.1%, which is below the limit of quantification. The stability of the chelate in plasma is better than that of 1-Gadopiclenol.
[0203] Effect Test Example 4 Water Solubility Measurement
[0204] The water solubility of the compound was determined in 0.5 mL of buffer solution (10 mM Tris-HCl) at room temperature (20 °C) in a microcentrifuge tube. Measurement method: The solid compound was gradually added to the buffer solution, the suspension was mixed using an oscillator, and treated in an ultrasonic bath for 5 min until insoluble matter appeared. The solubility of the compound was calculated, which refers to the mass of solute dissolved in 100 g of solvent when the solid substance reaches saturation at a certain temperature. The measurement results are shown in the following table:
[0205] Table 4 Water solubility
[0206]
[0207] From the results in the above table, it can be seen that the solubility of compounds 1, 5, 8, 14 and 17 prepared by the present invention is greater than 1000 mg / 100 ml, and can be administered by intravenous injection as contrast agents.
[0208] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A chelate, characterized in that The chelate has the structure shown in formula (AO-II-1) and formula (AO-II-2): Wherein, n is selected from an integer between 1 and 6; R5 is selected from H, C1-C2 alkyl; R4 is , wherein R6 and R7 are selected from H or -CH2OH, and m is selected from an integer between 0 and 4. When m is 0, it means that the -CHOH- group does not exist.
2. The chelate according to claim 1, characterized in that The chelate has the structure shown in formula (AO-III-1a) and formula (AO-III-2a): In the formula, n is selected from 1, 2 or 3; m is selected from 0, 1, 2, 3 or 4, when m is 0, it means that the -CHOH- group does not exist; R5 is selected from H, -CH3.
3. The chelate according to claim 1, characterized in that The chelate has the structure shown in formula (AO-III-1b) and formula (AO-III-2b) wherein n is selected from 1, 2 or 3; R5 is selected from H, -CH3; R8, R9, R 10 are each independently selected from H or -CH2OH, and R8, R9, R 10 At least one of them is -CH2OH.
4. The chelate according to claim 1, characterized in that The chelate has the following structural formula: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 5. A method for preparing a chelate, comprising the following steps: ; Wherein, G is -OH or -OCH3; n is selected from an integer between 1 and 6; R5 is selected from H, C1-C2 alkyl; R4 is ,in, R6 and R7 are selected from H or -CH2OH, m is selected from an integer between 0 and 4, when m is 0, it means that the -CHOH- group does not exist; As shown in the above formula, compound M2 is dissolved in water, the pH is adjusted to 6, compound M1 and dioxane are added, HOBT and EDCI are added under stirring, the pH of the reaction solution is adjusted to 6, the reaction is carried out for 24 hours, and the solution is concentrated under reduced pressure. An equal volume of ethanol and ether are added to disperse the solid, and the solution is filtered and separated by reverse phase preparative chromatography to obtain chelate M.
6. A pharmaceutical composition comprising the chelate according to any one of claims 1 to 4, and a pharmaceutically acceptable excipient.
7. Use of the chelate according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 6 in the preparation of a contrast agent for magnetic resonance imaging.
Citation Information
Patent Citations
Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
CN101305006A
Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
CN103224495A
Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them
US5403572A
System and method for treatment and outcome measurement analysis
US6450956B1
Bicycle-polyazamacrocyclocarboxylic acid complexes, conjugates, preparation and use as contrast agents
WO1993011800A1
